Our principal investigators Dr. Ahmed and Dr. Levinson have completed more than 200 clinical trials, phase I, II, III and IV in many therapeutic areas such as Type 2 Diabetes, Cardiovascular Disease, Obesity, Hyperlipidemia, Hypertension, Chronic Kidney Disease.
Dr. Ahmed and Dr. Levinson have together published more than 81 publications in many reputable journals. Below are a few links to their publications.
Our Global Presence from USA to JAPAN
- Abbott
- AbbVie
- Amgen
- Astellas Pharma
- AstraZeneca
- Bayer
- BioDelivery Sciences Intl.
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo Company
- Eli Lilly and Company
- Esperion Therapeutics
- Genentech
- Gilead
- GlaskoSmithKline
- Hisamitsu Pharmaceutical Co.
- Hoffmann-LaRoche
- Janssen
- Johnson and Johnson
- Kowa Pharmaceuticals America
- MannKind Corporation
- Merck
- Mylan
- Novartis
- Novo Nordisk
- Orexigen Therapeutics
- Pfizer
- Purdue Pharma
- Quantum Genomics
- Regeneron Pharmaceuticals
- Roche
- Samumed
- Sanofi
- Semnur
- Sucampo Pharmaceuticals
- Takeda
- Teva Pharmaceutical Industries
- The Medicines Company
- Theracos
Listed below are the compounds that Dr. Ahmed and Dr. Levinson have worked on as Principal Investigators.
- Adalimumab
- ALN-PCSSC
- Alogliptin
- Alosteron
- Amlodipine
- Androgel
- ASP1941
- Atrasentan
- Bardoxolone Methyl
- Bexagliflizin
- BI 695500
- BI 695501
- BMP-7
- Bococizumab
- Calcifediol
- Canagliflozin Choline
- Fenofibrate
- Clonidine HCl
- Tpical Gel 0.1%
- CTP-499
- Dapagliflozin
- Darbepoetin
- Alfa Diacerein
- Diacerein
- Dutogliptin
- Elagolix
- Empagliflozin
- Epotein Alfa
- Etanercept/Enbr
- Evolocumab
- Exenatide
- Fasinumab
- Fulranumab
- GSK189075
- GSK3196165
- HKT-500
- Hydrocodone
- Extended- release Insulin
- Detemir Insulin
- Insulin Glargine/Lixisen atide (LixiLan)
- JTT-851
- Linaclotide
- Linagliptin el
- Liraglutide
- Lixisenatide
- Lubiprostone
- MOA-728
- Mylan Insulin Glargine
- Naltrexone SR/Bupropion SR
- Nebivolol
- Oravescent
- Fentanyl Citrate
- Oxycodone/Nal oxone
- Peginesatide
- Pemafibrate
- Perindopril
- Pioglitazone HCl
- PT003
- PT009
- PT010
- QGC001
- Regadenoson
- Repaglinide/Metf ormin
- Rituximab
- RO6807952
- Roxadustat
- SAR425899
- Semaglutide
- SM04690
- Sotagliflozin
- TAK-875
- Tanezumab
- Tapentadol
- Ticagrelor
- Tocilizumab
- Tujeo (Insuline Glargine 300U/L)
- Valsartan
For more information on our research site or Sponsor / CRO inquiries, please contact:
Nusrat Deen
Director of Clinical Research
Phone: (312) 823-6800
Email: ndeen@apexmedicalresearch.com